靶向沉默Tmprss6减轻MDS小鼠铁诱导炎症并延长生存
在NUP98-HOXD13(NHD13)MDS小鼠模型中,每月皮下注射GalNAc偶联siRNA(SLN124)3 mg/kg或口服去铁酮1.25 mg/mL,SLN124最显著减少组织铁沉积与ASC斑点,并延缓疾病进展、延长生存。
要点
- MDS小鼠铁负荷与CD45+细胞ASC斑点形成强相关,提示炎症小体激活。
- SLN124与去铁酮均减少组织铁沉积和ASC斑点,SLN124效果最显著。
- 长期SLN124治疗使30%小鼠存活超过450天,对照与去铁酮组至第420天全部死亡。
核心结论
- 通过SLN124抑制Tmprss6可抑制铁驱动的炎症并减轻MDS小鼠疾病进展,提示TMPRSS6沉默是潜在的疾病修饰治疗策略。
研究设计与样本
- 研究在NUP98-HOXD13(NHD13)MDS小鼠模型中进行,MDS与野生型小鼠每月皮下接受SLN124(3 mg/kg)或口服去铁酮(1.25 mg/mL)。
主要发现
- MDS小鼠铁负荷与CD45+造血细胞中ASC斑点形成强相关,符合炎症小体激活。
- SLN124与去铁酮均减少组织铁沉积和ASC斑点丰度,SLN124效果最显著。
- 长期SLN124治疗延缓疾病进展并显著延长生存,30%治疗小鼠存活超过450天,而对照与去铁酮组至第420天全部死亡。
关键数值与推荐
- SLN124剂量为3 mg/kg,每月皮下注射;去铁酮为1.25 mg/mL口服。
- SLN124组30%小鼠存活超过450天,对照与去铁酮组至第420天全部死亡。
临床怎么用
- 该结果支持在MDS中进一步评估靶向TMPRSS6以增加内源性hepcidin、限制铁过载及其炎症后果的策略。
局限性
- 研究基于NHD13小鼠模型,尚未提供人体临床数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Despite advances in supportive and targeted therapies, disease-modifying interventions remain limited. Iron overload is increasingly recognized as a key driver of disease progression, amplifying oxidative stress and inflammation while impairing hematopoietic function. However, the mechanisms by which sustained iron excess contributes to disease evolution remain poorly understood. Hepcidin, the master regulator of systemic iron homeostasis, is produced by hepatocytes in response to iron and inflammatory cues and is negatively regulated by transmembrane protease serine 6 (TMPRSS6). Targeting TMPRSS6 to increase endogenous hepcidin offers a promising strategy to restrict iron overload and its inflammatory consequences. Here, we investigated hepatocyte-targeted silencing of Tmprss6 using a GalNAc-conjugated siRNA (SLN124) in the NUP98-HOXD13 (NHD13) mouse model of MDS. MDS and wild-type mice received monthly subcutaneous SLN124 (3 mg/kg) or oral deferiprone (1.25 mg/mL). Iron burden in MDS mice strongly correlated with ASC-speck formation in CD45+ hematopoietic cells, consistent with inflammasome activation. Both SLN124 and deferiprone reduced tissue iron deposition and ASC-speck abundance, with SLN124 producing the most pronounced effect. Long-term SLN124 treatment delayed disease progression and significantly prolonged survival, with 30% of treated mice surviving beyond 450 days compared with complete mortality by Day 420 in controls and deferiprone-treated mice. These findings demonstrate that Tmprss6 inhibition via SLN124 suppresses iron-driven inflammation, and mitigated disease progression in MDS mice, establishing TMPRSS6 silencing as a promising disease-modifying therapeutic approach.
引用
- Vilcassim S, Pholngam N, Thubthed R, et al. Therapeutic Silencing of Tmprss6 Reduces Iron-Induced Inflammation and Prolongs Survival in MDS Mice. Am J Hematol. 2026. PMID: 42240074. doi:10.1002/ajh.70391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。